[角色] 你是一名拥有10年投资银行从业经验的资深研究分析师，专门负责上市公司、行业研究。你擅长解读公司财报、行业动态、宏观市场，发现潜在的投资机会和风险。 [任务] 你需要仔细研读一份上市公司或者行业研究的电话会议记录，请阅读全文，一步一步思考，总结全文列出关键要点，不要错过任何信息，包括： * 纪要涉及的行业或者公司 * 纪要提到的核心观点和论据 * 其他重要但是可能被忽略的内容 如果没有相关内容，请跳过这一部分，进行其他的部分。 总结时要全面、详细、尽可能覆盖全部的内容、不遗漏重点,并根据上述方面对内容进行分组。 要引用原文数字数据和百分比变化,注意单位换算(billion=十亿,million=百万,thousand=千)。 [注意事项] 1) 使用中文,不要出现句号 2) 采用markdown格式 3) 不使用第一人称,以"公司"、"行业"代替 4) 只输出关于公司和行业的内容 5) 在每一个关键点后用[序号]形式引用原文档id 6) 一个[序号]只应该包含一个数字，不能包含多个，如果多个就用[序号][序号]分开写，不要写成 [序号-序号] 7) 每个关键要点后边的 [序号] 不要超过 3 个 Content: --------- <doc id='1'>ab 25 September 2025 China Medtech Expert call takeaways: Pulse check on China's IVD market China IVD market update for Q325 We hosted an expert call with Mr. Fang, an in-vitro diagnostics (IVD) distributor with over 15 years of industry experience. The key topics included: 1) market size, test volume, channel inventory and the competitive landscape in Q325; 2) the implementation status and impact of existing policies in relation to test volume and test fee/reagent prices; and 3) the expert's estimates of market growth and potential competitive dynamics in Q425/2026.</doc> <doc id='2'>Q325 results likely to diverge across test types According to the expert, the market growth in regions under his analysis was as follows: 1) Chemiluminescent immunoassay (CLIA): -17% YoY in test volume and -25% YoY in revenue. Volume declined QoQ, with a negative impact from panel test unbundling policies. On a monthly basis, the expert noted stabilisation of test volume in September 2025 following declines in July-August. 2) Clinical chemistry: -8% YoY in volume and revenue. Similar to CLIA, the QoQ volume decline for clinical chemistry tests was mainly reflected in July-August 2025. 3) Haematology: +8% YoY in volume and +6% YoY in revenue. The QoQ volume decline was less than 2%, primarily attributable to an off- season for physical examinations. 4) Haemostasis: +3% YoY in volume and revenue. Test volume was largely flat QoQ. 5) Point of care tests (POCT): -12% YoY in volume and revenue. Test volume was largely flat QoQ.</doc> <doc id='3'>Channel destocking close to an end; import substitution status varies by test With respect to channel inventory, the expert highlighted the following: 1) CLIA: For global brands, channel inventory is equivalent to 10-12 weeks of sales. For local brands, it is equivalent to 8-10 weeks of sales. 2) Haematology: Leading players had channel inventory equivalent to ~6 months of sales last year and have had channel destocking YTD. In terms of import substitution, the expert noted the following: 1) CLIA: Import substitution was accelerated by volume-based procurement (VBP) in Q325, with domestic brands more accepted by grade A tertiary hospitals; the trend is likely to extend into Q425-2026. 2) Clinical chemistry: A stable competitive landscape, with domestic brands commanding a large share. 3) Haematology: Import substitution in lower-tier markets and even some top-tier hospitals; the expert expects the trend to be sustained in Q425-2026. 4) Haemostasis: Ongoing import substitution but at a relatively slow pace.</doc> <doc id='4'>The expert estimates market growth in 2026 for major tests, except CLIA Overall, the expert expects sector-wide test volume to bottom out in Q425, with the negative impact of the test unbundling policy largely reflected. In terms of the 2026 outlook, he thinks major test categories are likely to grow YoY, except for CLIA, for which revenue may continue to decline YoY, given a relatively high base for reagent prices. According to the expert: 1) CLIA: The market size could shrink 10%+ YoY as new prices for tumour biomarkers and thyroid function reagents are implemented in Q425. The inflection point is most likely to occur in Q426, but it could be as early as Q326. 2) Clinical chemistry: The expert expects market growth below 5% in 2026. 3) Haematology: There is high growth visibility, with a relatively low likelihood of VBP; the expert expects c10% growth in 2026. 4) Haemostasis: The expert thinks this category has a relatively high possibility of VBP. That said, 10% market growth in 2026 could be feasible without VBP.</doc> <doc id='5'>Equities China Healthcare Jun Deng Analyst jun.deng@ubs.com +852-3712 2103 Emma Ma, CFA Associate S1460124070003 emma-mc.ma@ubs.com +86-21-3866 8981 Chen Chen, PhD Analyst chen-zb.chen@ubs.com +86-10-5832 8201 This report has been prepared by UBS Securities Asia Limited. ANALYST CERTIFICATION AND REQUIRED DISCLOSURES, including information on the Quantitative Research Review published by UBS, begin on page 6. UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.</doc> <doc id='6'>Expert call key takeaways We hosted an expert call with Mr. Fang, an IVD distributor with over 15 years of industry experience. Below, we present highlights from the meeting. We have made edits for clarity; minor grammatical changes that do not impact the meaning of content have been applied. The opinions expressed by the expert herein do not necessarily reflect the views and opinions of UBS. UBS accepts no responsibility for the accuracy, reliability or completeness of the information and will not be liable either directly or indirectly for any loss or damage arising out of the use of this information or any part thereof.</doc> <doc id='7'>1. What do you see for China's IVD market growth by revenue and test volume in Q325? According to the expert, the market growth in regions under his analysis was as follows: 1) Chemiluminescent immunoassay (CLIA): -17% YoY in test volume and -25% YoY in revenue. Volume declined QoQ, with a negative impact from panel test unbundling policies. On a monthly basis, the expert noted stabilisation of test volume in September 2025 following declines in July-August. 2) Clinical chemistry: -8% YoY in volume and revenue. Similar to CLIA, the QoQ volume decline for clinical chemistry tests was mainly reflected in July-August 2025. 3) Haematology: +8% YoY in volume and +6% YoY in revenue. The QoQ volume decline was less than 2%, primarily attributable to an off- season for physical examinations. 4) Haemostasis: +3% YoY in volume and revenue. Test volume was largely flat QoQ. 5) Point of care tests (POCT): -12% YoY in volume and revenue. Test volume was largely flat QoQ.</doc> <doc id='8'>2. For the haematology business, why did the top two players have notable revenue declines in Q225? In Q225, Mindray and Sysmex had notable revenue declines YoY for the haematology business. This was the opposite of the market expansion observed by the expert. For example, Dymind, the third-largest player in the market, had 10%+ growth in volume and revenue in the first nine months of 2025. In addition, Maccura, another key player, saw single-digit growth in H125.</doc> <doc id='9'>As per the expert, Sysmex's revenue decline in Q225 may be attributable to import substitution and channel destocking. For Mindray, potential reasons for the revenue decline in the quarter include channel destocking and a high revenue base last year.</doc> <doc id='10'>3. What is the level of channel inventory for reagents across test categories? Will channel destocking continue to pressure companies' revenue growth in the near future? At the sector level, the expert estimates channel inventory as of Q325 to be as follows: 1) CLIA: For global brands, channel inventory is equivalent to 10-12 weeks of sales. For local brands, it is equivalent to 8-10 weeks of sales. 2) Clinical chemistry: Not much change in Q325. 3) Haematology: Leading players had channel inventory equivalent to ~6 months of sales last year and have had channel destocking YTD. The expert believes channel destocking may be close to an end for Mindray's haematology business. Heading into Q425, the expert expects a limited impact from channel destocking for leading domestic companies such as Mindray, with relatively low channel inventory in haematology, CLIA and clinical chemistry.</doc> <doc id='11'>4. What is the potential market growth across test categories in Q425-2026? Overall, the expert expects sector-wide test volume to bottom out in Q425, with the negative impact of the test unbundling policy largely reflected.</doc> <doc id='12'>In terms of the 2026 outlook, he thinks major test categories are likely to grow YoY, except for CLIA, for which revenue may continue to decline YoY, given a relatively high base for reagent prices. According to the expert: 1) CLIA: The market size could shrink 10%+ YoY as new prices for tumour biomarkers and thyroid function reagents are implemented in Q425. The inflection point is most likely to occur in Q426, but it could</doc> <doc id='13'>be as early as Q326. 2) Clinical chemistry: The expert expects market growth below 5% in 2026. 3) Haematology: There is high growth visibility , with a relatively low likelihood of VBP; the expert expects c10% growth in 2026. 4) Haemostasis: The expert thinks this category has a relatively high possibility of VBP. That said, 10% market growth in 2026 could be feasible without VBP.</doc> <doc id='14'>5. What are the current status and potential outlook of import substitution across test categories? 1) CLIA: Import substitution was accelerated by VBP in Q325, with domestic brands more accepted by grade A tertiary hospitals; the trend is likely to extend into Q425- 2026. 2) Clinical chemistry: A stable competitive landscape, with domestic brands commanding a large share. 3) Haematology: Import substitution for local brands, such as Mindray, Dymind and Urit, in some top-tier hospitals, as well as continued import substitution in lower-tier markets; the expert expects the trend to be sustained in Q425- 2026. 4) Haemostasis: Ongoing import substitution but at a relatively slow pace.</doc> <doc id='15'>For Mindray specifically, the expert sees market share gain potential across test types. For example, he believes it could be feasible to gain 2% share annually in CLIA market in the next three years. That said, the potential market share gain in haematology could be modest, given its high market share.</doc> <doc id='16'>6. What will be the actual impact of test volume-related policies in Q325? When do you expect these policies' impact to fade? Can any potential new policies further erode test volume? According to the expert, the test unbundling policy could lead ~15%/~5% volume declines YoY for CLIA/clinical chemistry in Q325. In contrast, the expert thinks there will be a limited impact for haematology and haemostasis. The expert expects the policy impact to fade in Q425, as test unbundling may be largely completed by September 2025. In addition, a few regions had rebundling for some panel tests that were previously unbundled.</doc> <doc id='17'>Beyond test unbundling, the expert foresees a very limited additional impact from DRG implementation and mutual recognition of test results. Moreover, he does not think there will be more new policies to further erode test volume at the sector level.</doc> <doc id='18'>7. For the VBP of tumour biomarkers and thyroid function reagents, what are the likely implementation timeline and ex-factory price cuts? The expert expects this round of VBP to be implemented starting in October 2025 and to cover most of the participating provinces by December 2025. The ex-factory price adjustment has not been completed yet, although a few companies have adjusted thyroid function reagent prices following the previous VBP in Gansu.</doc> <doc id='19'>On the magnitude of ex-factory price cuts, the expert thinks domestic companies may have 20%+ cuts for tumour markers and 10%+ cuts for thyroid function reagents. For overseas companies, the expert expects further price erosion for tumour biomarkers reagents on top of the price revisions following the previous testing fee correction. For thyroid function reagents, the ex-factory price cuts could reach c30%.</doc> <doc id='20'>8. Which reagents are likely to be covered by the next round of VBP? What is the potential timeline? The expert reiterated his view that CLIA will be the priority for VBP in 2026. Implementation is likely to start in 2027, although the impact could be limited, as major test items under CLIA have been covered by VBP. In addition to CLIA, the expert now thinks the VBP of haemostasis tests may take place in 2026 or 2027. Similar to CLIA, it may take about one year from the result announcement to official implementation for haemostasis VBP, in the expert's view.</doc> <doc id='21'>9. What is the potential impact of Hunan Province's recent test-fee correction for drug-resistant tuberculosis molecular testing? Which tests may be subject to a test-fee correction going forward? The expert expects a limited impact from this initiative, considering the small market size of tuberculosis-related tests in China (Rmb300m+ in total, with the market size of drug- resistant tuberculosis tests amounting to Rmb100m+). Overseas companies such as Cepheid (a member of Danaher Group) and domestic companies such as Zeesan, Ustar and Wantai may have some impact, as per the expert.</doc> <doc id='22'>The expert noted that tests with particularly high fees will be the focus of the upcoming testing fee correction. Thus, the main focus could be CLIA, such as tumour biomarkers, infectious diseases, thyroid functions and myocarditis tests.</doc> <doc id='23'>Valuation Method and Risk Statement We believe the risks facing China's medtech industry include: 1) larger-than-expected price reductions and smaller-than-expected market share gains from medical device VBP programs; 2) weaker-than-expected demand from equipment renewal programs; 3) a greater-than- expected impact from the anti-corruption drive; 4) geopolitical risks affecting the supply chain of medical device products; and 5) slower-than-expected product R&D and technological breakthroughs.</doc> <doc id='24'>Required Disclosures This document has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including former Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".</doc> <doc id='25'>For information on the ways in which UBS manages conflicts and maintains independence of its UBS Global Research product; historical performance information; certain additional disclosures concerning UBS Global Research recommendations; and terms and conditions for certain third party data used in research report, please visit https://www.ubs.com/disclosures. Unless otherwise indicated, information and data in this report are based on company disclosures including but not limited to annual, interim, quarterly reports and other company announcements. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 25 September 2025 03:15 PM GMT. UBS has designated certain UBS Global Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. Quantitative Research Review: UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For the latest responses,

涉及的行业或公司 * 公司为京东 (JD O) [1] * 行业涉及中国电子商务、人工智能、物流、零售、医疗健康和工业制造 [1][2][6][7][8][9] 核心观点和论据 公司战略与AI投资 * 京东更新了对AI价值的看法，认为AI价值 = 模型 × 经验 × 对行业的深入理解 [2] * 京东宣布未来三年将投资培育一个价值万亿人民币的AI生态系统 [2] * 公司旨在通过其在各行业垂直领域的供应链技术积累的专业知识，实现AI的可持续发展，为行业带来价值 [2] 新产品与技术发布 * 京东宣布其升级后的大型模型品牌 JoyAI，并发布了三款面向个人消费者的新AI产品 [3][5] * "京犀"：集成AI的购物和本地生活超级应用，支持语音控制交易 [5] * "Ta"：通用数字助理代理，可创建AI代理并嵌入智能硬件 [5] * "JoyInside Embodied Intelligence"：软硬件集成解决方案，已使用户主动对话平均增长超过120%，并被30多个顶级品牌和10多家领先机器人公司采用 [6] * 京东宣布升级三大AI基础设施：数字人平台4.0、JoyAgent 3.0智能平台和JoyCode 2.0编码平台 [10] 行业应用与效率提升 * 京东在四个关键领域宣布了AI进展 [6] * **物流**：升级了全多模态的物流超级大脑大模型2.0，并发布首款"智能机械臂"以解决大量非标准化包裹的自动化问题，旨在提高物流和仓储效率及准确性 [7] * **零售**：推出基于JoyAI模型的Oxygen电商AI架构，并在10月发布的JD应用16.0版本升级中增加智能搜索和推荐功能"Aigou"，利用自然语言交互提供个性化购物体验 [8] * **医疗健康**：推出行业"首个"能理解医疗报告和患者描述的医疗大模型"京医千寻2.0"，并赋能新的JD Health AI Hospital 1.0 [9] * **工业**：发布行业"首个"工业供应链大模型JoyIndustrial，基于超过5700万种产品的数据训练，旨在提高效率并降低成本 [9] * 分析认为京东的AI物流和电商供应链解决方案将提升运营效率并优化行业流程，增强其对其供应链合作伙伴的价值主张和竞争力 [1] 财务分析与投资建议 * 花旗维持对京东的"买入"评级，目标价为44美元，基于12倍2026年非GAAP每股收益3.66美元 [1][11] * 目标市盈率隐含相对于2025-2027年预计收益复合年增长率23%约50%的折价，该折价被认为是合理的，因京东积极进军外卖等可能损害其利润增长且竞争和支出正常化时间不确定的领域 [11] * 当前股价为35.17美元，预期股价回报率为25.1%，预期股息收益率为3.7%，预期总回报率为28.8%，市值为565.48亿美元 [3] 其他重要内容 潜在风险 * 主要下行风险包括：1) 中国电商和外卖领域竞争加剧 2) 对物流配送和海外计划的大量投资可能拖累利润率 3) 利润率轨迹和早期盈利能见度不足 4) 中国经济进一步放缓可能影响消费者支出 [12] 市场背景 * 分析认为中国正进入AI应用加速期，互联网和其他技术平台加大投资推动了多种类型的AI技术创新 [1] * 除了像阿里云这样的云基础设施提供商的LLM，预计将看到更多垂直平台参与投资/发布行业AI模型/解决方案，利用其核心专业领域的经验和知识来支持其垂直业务合作伙伴 [1]

Equity Research 25 September 2025 U.S. Semiconductors & Semiconductor Capital Equipment NVDA's Vision Coming to Life: $2T and Counting When tracking AI capacity additions over the LTM, AI TAMs don't seem so outlandish anymore and NVDA looks like the most interesting name in our group. When Jensen first forecast a $1T industry by the end of the decade, we admittedly balked. With the wave of announcements that have come over the last 6-9mo, we now estimate over $2T of planned spend at ~40GW of power in total. ...

September 28, 2025 08:11 PM GMT Yili Industrial | Asia Pacific NDR Feedback - Focus on Raw Milk Supply Cycle and Key Product Category Strategy Key Takeaways Key questions from investors: 1. When will raw milk reach supply/demand balance? Management cited two positive signs: cow herds dropping sequentially and non-contractual raw milk prices rebounding. It expects a balance in 2026. 2. What are the next 3-5 year targets? Yili is still drafting its next 5-year plan. General directions are for: 1) liquid milk ...

**行业与公司** * 涉及中国宏观经济与货币政策[1] * 涉及中国工业利润与原材料行业（如钢铁）[4] * 涉及中国政府债券（CGB）市场[1][2][3] **核心观点与论据** * 中国人民银行货币政策立场未变 第三季度货币政策委员会声明与第二季度基本一致 但不再将经济描述为“显示积极势头” 原因是近几个月经济数据疲软[1] * 长期中国政府债券收益率持续攀升 原因是债转股轮动以及市场对CGB投资增税的预期 图表显示10年期和30年期CGB收益率走势[1][2][3] * 尽管仍预期第四季度有政策利率和存款准备金率下调 但鉴于央行近期强调数据依赖性 可能需要经济活动显著疲弱才会触发[1] * 8月工业利润显著改善 环比增长8.0% 高于7月的3.7%增长 但工业收入在过去两个月基本保持不变[4][9] * 钢铁等原材料行业盈利能力显著改善 暗示政府的“反内卷”政策正在发挥作用 但国家统计局评论称8月利润改善主要得益于成本降低 这凸显了中国对抗通缩的难度[4] * 欧洲投资者对中国科技与创新中期展望普遍持建设性态度 但对近期的通缩、企业盈利和家庭消费存在持续担忧 对人民币看法不强 因美元方向不明 对中国利率看法分歧 部分客户认为债转股轮动可能推动长期CGB收益率进一步走高 另一部分则认为这可能是做多的机会[10] **其他重要内容** * 文档包含大量监管披露、免责声明和法律合规信息 强调研究报告仅供参考 不构成个人投资建议 投资者应自行决策并注意风险[5][15][16][17][18][25][26][27][28][31][38] * 列出了高盛近期关于中国宏观经济的部分研究报告标题 涵盖家庭储蓄、产能过剩、出口、PMI、CPI、房地产价格等多个主题[11][13] * 提供了分析团队成员的姓名和联系方式[6]

**行业与公司** 行业聚焦中国/香港消费板块 涵盖多个子行业包括运动服饰、玩具、珠宝、啤酒、乳制品、家电、餐饮等[1][4][7] 涉及公司包括但不限于安踏体育(ANTA Sports Products)、李宁(Li Ning)、泡泡玛特(Pop Mart International Group)、老铺黄金(Laopu Gold)、申洲国际(Shenzhou International)、巨子生物(Giant Biogene)、百胜中国(YUMC)、蒙牛乳业(China Mengniu Dairy)、青岛啤酒(Tsingtao Brewery)等[7][58][60][62] **核心观点与论据** * 国际投资者对中国消费板块持仓较轻但兴趣提升 近期在美国、欧洲和新加坡举行路演活动 会见超过70家机构客户[3][7] * 宏观层面关注消费复苏轨迹和政策影响 多数投资者认为基本面全面复苏需要时间 资金轮动是重要变量 存在落后补涨风险[3][7] * 股票层面兴趣集中于少数公司 但地区关注点不同 美国投资者偏好 idiosyncratic机会如泡泡玛特 而欧洲和新加坡投资者兴趣更广泛覆盖多个子行业[3][7] * 新兴投资角度包括：1)在消费降级环境中能维持高端定位并拥有定价力的品牌 2)财富效应转移时的受益者[3][7] * 消费驱动因素：潜在支持性政策和受益品类 2026年可能出台补贴措施 股市上涨可能带来积极的财富效应[7] **其他重要内容** * 泡泡玛特是最具争议的公司 市场关注社交媒体狂热/Labubu系列 但忽视了其复购客户积累和丰富的IP/产品供应 供需动态是热门话题 部分投资者将其与其他流行收藏品(如运动/Pokemon卡片)比较[7] * 运动服饰关注安踏、Amer、李宁的需求趋势和选股[7] * 老铺黄金关注价值主张、长期增长驱动力 与欧洲奢侈品牌和国内珠宝品牌的竞争[7] * 代工企业关注关税影响 鞋服供应商中更具优势的玩家 申洲国际关注客户基础、订单流和利润率趋势驱动的销售增长[7] * 巨子生物关注进入壁垒、需求持久性和利润率趋势[7] * 百胜中国关注外卖补贴的影响[7] * 啤酒/乳制品关注潜在复苏[7] * 家电关注国家补贴和海外机会[7] * 摩根士丹利披露其与覆盖的多家公司存在业务往来 包括投资银行业务、做市等 并持有部分公司1%或以上普通股[13][14][15][16][17][18][19]

29 September 2025 | 7:24AM CST Equity Research CHINA SOLAR: TRACKING PROFITABILITY INFLECTION Sep Poly/Glass price above expectation, but likely to be reversed as downstream inventory piles up Our China Solar Profitability Tracker follows monthly supply/demand and inventory dynamics by sub-sector, and the spot prices/input costs implied cash GP & EBITDA margin trends for companies under our coverage. Key highlights in Sep MTD: Jacqueline Du +852-2978-1783 | jacqueline.du@gs.com Goldman Sachs (Asia) L.L.C. c ...

**公司及行业** 公司为药明康德（WuXi AppTec Co. 2359.HK/603259.SS） 行业为医药研发外包服务（CRO/CDMO）[1][10] **核心业务模式与市场地位** - 公司强调其CRDMO（合同研究、开发与生产）业务模式的优势 聚焦于获取新项目、增强客户黏性及捕捉新兴机会[1] - 在小分子药物领域保持稳定市场份额 D端（开发端）市占率为16% 2024年至2025年上半年在40个获批小分子项目中捕获约20%份额[6] - 客户留存率高达98% 前300名客户贡献70%总业务[5] 使用发现与临床前平台的客户数量达1000家（2023年为900家） 全流程服务收入占比提升至74.4%（原73.2%）[5] **技术能力与新兴机会** - TIDES业务（包括多肽和寡核苷酸）增长显著 环肽进入大规模商业化生产 核酸产品处于PPQ（工艺验证）阶段 当前聚焦罕见病但具备扩展潜力[5] - 技术优势包括流动化学、光化学技术等 支持新模态药物开发[5] - 早期项目参与助力捕捉新靶点研发趋势 治疗领域扩展至抗感染、神经科学、代谢及免疫炎症等非肿瘤领域[5] **运营效率与数字化进展** - 生物学业务通过数字化运营、DMPK软件及生物分析平台提升效率 2025年上半年项目周转时间同比减少30% 分析时间减少35%[7] - 生产基地投产时间从2017年22.6个月大幅缩短至2024年2.4个月[7] - 数字化系统覆盖90%运营流程 API产能利用率提升至72%（去年68%） 小分子和肽生产自动化分别达90%和80%[7] - "鹰眼"系统降低错误率并提高成功率 FDA审计零缺陷[7] **海外产能扩张与战略布局** - D&M（开发与生产）产能投资占比升至85%（早期为28%）[8] - 药品生产（DP）成为新增长引擎 2025年上半年69个TIDES分子同时使用API和DP服务[8] - 泰兴基地：过去12个月投产4个新工厂 二期两车间建设周期仅11-12个月（对比常州基地一期/二期63个月）[8] - 新加坡：首个小分子工厂预计2027年1月投产 首座TIDES工厂预计2028年二季度投产[8] - 瑞士库韦站点：口服剂量包装产能翻倍 新建PSD-4喷雾干燥大楼预计2026年四季度完工[8] - 美国基地：预计2026年四季度运营 2027年底前上线无菌灌装产能 将成为公司最大海外设施[8] - 新加坡肽产能和美国OSD（口服固体制剂）产能有望捕捉肥胖治疗机遇[8] **财务预测与风险提示** - 高盛给予H股目标价96.9港元（当前107.6港元 下行空间9.9%） A股目标价93.3元（当前102.92元 下行空间9.3%） 基于17倍12个月前瞻市盈率[9][11] - 上行风险：若美国《生物安全法案》最终仅限制联邦资助项目或排除药明系公司[9][10] - 下行风险：1）法案极端情景导致美国或海外收入归零 2）国内外同行价格竞争 3）监管与融资风险 4）成功导向型业务模式不确定性 5）新业务增速不及预期[9][10] - 财务预测：2024-2027年收入预计为392.4亿/440.0亿/493.7亿/551.9亿元 每股收益为3.23/4.99/5.34/5.91元[11] **其他重要信息** - 公司M&A评级为3（被收购概率0%-15%）[11][17] - 高盛持有药明康德A股和H股超过1%股权 并在过去12个月提供投资银行服务[21]

涉及的行业与公司 **行业** 中国工业行业 重点关注智能机器人和人形机器人领域[1][7] **涉及公司** - 机器人制造商与集成商：汇川技术（Inovance）、埃斯顿（Estun）、遨博（Dobot）、奥比中光（Orbbec）、舍弗勒（Schaeffler）、无锡信捷（Wuxi Xinje）[5][10] - 其他相关企业：双环传动（Shuanghuan）、极智嘉（Geek+）、中检集团（Centre Testing）等[5][33] --- 核心观点与论据 **1 智能机器人商业化加速，渗透率快速提升** - 协作机器人（Cobots）在1H25出货量同比增长47%，远超行业16%的增速[13] - 性能显著提升：埃斯顿Codroid协作机器人最大负载达50kg，速度、精度和负载能力进步驱动应用增长[13] - 应用场景扩展：从传统3C、汽车延伸至美妆、玩具、商业等领域[13] - 复合机器人（AGV/AMR底盘+机械臂）成为关键解决方案，已在3C（如苹果、英伟达）、焊接、物流、食品行业测试/应用[14][15] **2 人形机器人处于产品开发阶段，痛点明确但迭代迅速** - 展示多但实际工作流程集成有限，行业聚焦解决产品开发痛点[4] - 已公布订单总额接近10亿元人民币（1.4亿美元），但实际工业工作流集成需时（因效率、成功率和ROI要求高）[20] - 汇川技术预计全球销量从2025年1万台增至2026年10万台[20] - 舍弗勒强调需明确可扩展的工业应用场景[20] **3 供应链扩张加速，领先企业即将涌现** - 零部件/执行器供应商数量快速增加（传感器、螺丝、电机、减速器等），大公司推出标准化产品（如汇川、舍弗勒）[5] - 汇川技术人形部件已达中全球领先水平，预计2026年小批量订单，2028年螺丝产能达40万单位[24] - 舍弗勒倡导智能模块/标准组件趋势，强调体积和标准化是价格压缩关键[25] **4 技术路线多样化，AI与数据驱动创新** - 视觉方案：海外（特斯拉、FigureAI）多用2D视觉，国内集成商多采用结构光相机（如天工Pro搭载4个奥比中光Gemini相机）[23] - 模型架构：VLA（视觉语言动作）为主流，但数据缺乏是瓶颈；遨博质疑更多数据必然带来具身泛化，需模型架构创新[23] - 合成数据应用：遨博称约90%训练数据为合成数据[26] - 边缘计算：当前国产和英伟达芯片可支持，但未来通用模型需算力、能效比和散热改进[26] **5 合作与工作流重构成为成功关键** - 机器人协作规模扩大，由AI算法、硬件改进和工作流重构驱动[3] - 企业合作超越垂直供应链，预计集成商之间将加强协作[3] --- 其他重要内容 **行业活动与参与度** - CIIF展会设立专门人形机器人价值链展区，吸引450家供应链企业参与（2024年为350家），包括30家集成商和零部件供应商[2] **政府与政策支持** - 中国政府推动人形机器人初步应用[10] **风险与挑战** - 新材料（镁、PEEK）、新结构（轴向磁通/PCB电机）和陶瓷滚珠螺丝等技术验证需时，能见度低[23] - 当前模型仅能处理特定任务，需物理世界模型避免AI幻觉或漂移[23] **投资偏好** - 在人形机器人主题中偏好汇川技术和双环传动[5] **行业评级** - 摩根斯坦利对中国工业行业评级为“In-Line”（符合市场）[7]

涉及的行业与公司 * 行业：大中华区科技半导体行业，特别是专注于AI+AR智能眼镜的微投影、低功耗技术和相关半导体供应链 [1][7][110] * 公司： * **关键供应商**：Himax Technologies Inc (HIMX O) 和 OmniVision Integrated Circuits Group Inc (603501 SS)，两者均被给予增持评级，是LCoS显示技术的主要供应商 [1][5][110] * **品牌方**：Meta（推出Ray-Ban Meta Display）、Google（Project Aura路线图）、Amazon（计划推出消费者版眼镜）、阿里巴巴等中国品牌（如WoW Quark）[2][4] * **技术合作伙伴**：Lumus（提供阵列波导）、xMEMS（展示用于可穿戴设备的微冷却技术，是台积电特殊工艺客户）[2][3][26] * **潜在受益者**：SICC Co Ltd (688234 SS)，因SiC波导性能优于阵列和衍射方案而可能受益 [5] 核心观点与论据 * **AI+AR眼镜产品突破**： * Meta在Connect 2025推出的Ray-Ban Meta Display采用单目全彩LCoS+阵列波导显示方案，分辨率为600×600，刷新率90 Hz，视场角20°，峰值亮度达5000 nits以确保户外可读性 [2] * 设备电池续航声称达6小时，远超其原型Orion的45分钟，但交互依赖神经腕带，手势控制在主题演讲中出现故障 [2] * Meta同时更新了Ray-Ban Gen 2，电池续航延长至8小时，较上一代翻倍；Oakley Meta Vanguard将12 MP摄像头移至眼镜中心，支持3K视频 [9][17] * **关键技术趋势与创新**： * **低功耗LCoS**：Himax的0 17英寸双边缘照明前照式LCoS显示模块体积仅0 09立方厘米，重量仅0 21克，分辨率720×720，峰值亮度350,000 nits，总功耗仅250 mW，正在吸引主要眼镜品牌 [3][19] * **MEMS热管理**：xMEMS的微冷却技术针对设备总功耗从当前0 5-1W水平向2W及以上发展的趋势，热模型显示可提升60–70%的功率余量，降低系统温度达40%，降低热阻达75%，样品已提供，计划于2026年第一季度量产 [27][28][30] * **波导技术**：阵列波导（由Lumus供应）比主流衍射波导具有更优的光学效率，SiC波导被视为未来趋势 [2][5] * **市场前景与预测**： * 对智能眼镜半导体供应链保持乐观，因多家品牌有明确产品路线图 [4] * 预测AR设备中LCoS总目标市场到2028年将达到1 53亿美元 [42] * 预测AI眼镜的SoC总目标市场在2024年至2028年预测期间的复合年增长率为80% [47] * AI眼镜出货量预测显示，带摄像头的AI眼镜、不带摄像头的AI眼镜以及AI+AR眼镜类别均呈现增长趋势 [38][39] 其他重要内容 * **投资主题与风险**： * 对OmniVision、Himax和SICC等公司给出了具体的估值方法和风险提示 [48][49][52] * Himax的上涨风险包括AI眼镜等边缘AI设备的强劲出货拉动，下跌风险包括缺乏杀手级应用导致AI眼镜需求未达预期 [53][54] * **行业竞争格局**：除Meta外，美国和中国市场均有多个品牌积极推出或规划AI+AR眼镜产品，表明行业进入活跃发展期 [4] * **技术发展路线**：Himax宣布了下一代前照式LCoS解决方案，包括将现有0 17英寸面板像素尺寸从4 25微米缩小至3微米以将分辨率提升至1024×1024，以及开发0 1英寸面板将光学引擎体积显著减小至0 16立方厘米 [22]